CRISPR Therapeutics AG CRSP

Healthcare Biotechnology

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient’s hematopoietic stem a...

NDAQ:CRSP - Post by User

CRISPR Therapeutics AG

<< Previous

Bullboard Posts

Next >>

(4)
•••

Post by Lisaslabon Aug 24, 2022 12:44pm

226 Views

Post# 34917450

$4 billion CRISPR is a Switzerland-based biotechnology

biotechnology leader known for its cutting-edge platform to support gene editing and related development of genomic DNA medicines. It has a portfolio of therapies across a range of disease areas, including treatments for blood disorders, specialized cancers and other rare conditions.

<< Previous

Bullboard Posts

Next >>

Asus to cease smartphone production and shift fully toward AI